Children with type 2 diabetes have a new basal insulin schedule: once a week instead of once a day. On 23 October 2026, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae) injection 700 units/mL, the first once-weekly, long-acting basal insulin, as an adjunct to diet and exercise to improve glycemic control in children 10 years of age and older with type 2 diabetes. The approval gives families a basal insulin option that reduces injection frequency from seven times per week to one, a change Novo Nordisk frames as a way to reduce administration barriers tied to daily injections and to offer more individualised care.
What Was Approved
Awiqli is a prescription, long-acting insulin (U-700) used to control high blood sugar in adults and children 10 years and older with type 2 diabetes, and it is designed as an alternative to daily basal insulin. It is administered once weekly on the same day each week using the Awiqli FlexTouch pen, and Novo Nordisk notes that the dose counter always shows the selected dose in units and that patients should not convert doses from other insulins. The pediatric approval extends an existing adult approval: Awiqli was already approved in the United States, the European Union and 18 additional countries, with market-specific indications for diabetes, and the new approval adds children 10 and older with type 2 diabetes to the U.S. indication. It is not known if Awiqli is safe and effective in children less than 10 years of age, and the pen is not to be used with a syringe or in an infusion pump.
What the Evidence Showed
The pediatric approval is built on a combination of adult and pediatric evidence rather than a large pediatric efficacy trial. Novo Nordisk says the approval is supported by evidence from adequate and well-controlled studies in adults with type 2 diabetes and a single-dose pharmacokinetic study completed in pediatric patients aged 10 to under 18 that evaluated how once-weekly Awiqli behaves in that age group. Those results, together with efficacy and safety demonstrated in the pivotal ONWARDS clinical trial program, support use in pediatric patients at least 10 years of age. Becker's Hospital Review, reporting the approval, summarised the same evidence base: adult studies, a single-dose pharmacokinetic study in patients aged 10 to 17, and the ONWARDS program. Clinicians quoted by Novo Nordisk framed the need in adherence terms: Professor Eda Cengiz of the University of California, San Francisco said children with type 2 diabetes face an aggressive disease trajectory, that sustained glycemic control remains a major challenge, and that for more than 20 years daily basal insulin injections have been a main form of pediatric diabetes treatment, with some children facing challenges staying on a daily routine.
Safety and Practical Details
The safety profile Novo Nordisk published with the approval is the standard insulin picture, with the weekly schedule adding its own practical rules. Common side effects may include hypoglycemia (low blood sugar), serious allergic reactions, reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching, rash, swelling of the hands and feet, and weight gain. Patients should not use Awiqli during an episode of low blood sugar, and the pen should not be shared. Missed-dose instructions are specific to the weekly cadence: a missed dose should be taken as soon as possible if it has been four days or less, then the weekly schedule resumes a week from that day. If more than four days have passed, the missed dose should be skipped and the next dose taken on the regularly scheduled day. Novo Nordisk says Awiqli is available at more than 70,000 pharmacies nationwide, which matters for access, though availability at a specific pharmacy is a local check, not a guarantee in the announcement.
What This Means for Paediatric Diabetes Care
For pediatric and family practices, diabetes clinics and school-health teams, the approval changes the conversation about basal insulin more than it changes the medicine itself. A once-weekly schedule removes six injection moments a week, which can matter most for families where school-day injections, caregiver work schedules and adolescent independence make daily routines fragile. It also changes what clinics need to teach: same-day-each-week scheduling, the four-day missed-dose rule, site rotation, and the warning not to convert doses from other insulins are now part of the counselling checklist. Pharmacies and prior-authorization teams should expect questions about whether the pediatric indication is covered under a given plan, since a new indication does not automatically change coverage. The population context is growing: Novo Nordisk cites a modeling study anticipating that the number of people aged 19 and under with type 2 diabetes could reach nearly 84,000 by 2050, an estimate, not an observed count. Digitally, reminder systems become more valuable, not less, when the interval is weekly rather than daily: a missed weekly dose is a bigger share of therapy than a missed daily one, so portal and messaging reminders tied to the chosen injection day are worth setting up (see https://medclinicx.com/solutions/ai-patient-portal).
Analysis: Fewer Injections, More Room for Adherence
Analysis (MedClinicX): The most interesting part of this approval is what it does not claim. It does not claim a new efficacy breakthrough in children. It claims a schedule breakthrough, supported by adult efficacy data plus pediatric pharmacokinetic data. That is a reasonable regulatory path for a long-acting insulin, but it puts the burden of proof on real-world follow-up: glycemic control, hypoglycemia rates and persistence in children on a weekly schedule will only be visible in post-approval use. For clinics, the near-term opportunity is adherence support rather than promotion: families who struggled with daily injections now have a legitimate alternative to discuss, and the practices that build the weekly reminder, missed-dose counselling and coverage check around it will capture the benefit. The risk to watch is the opposite of the benefit: a weekly drug forgives fewer lapses than a daily one, so the reminder infrastructure matters as much as the prescription.
Sources and References
- Novo Nordisk via PR Newswire, Novo's Awiqli receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes, 23 October 2026: https://www.morningstar.com/news/pr-newswire/20261023ny79474/novos-awiqli-receives-fda-approval-as-the-first-and-only-once-weekly-insulin-for-children-10-years-of-age-and-older-with-type-2-diabetes
- Becker's Hospital Review, FDA approves 1st once-weekly insulin for children, 24 October 2026: https://www.beckershospitalreview.com/pharmacy/fda-approves-1st-once-weekly-insulin-for-children/
- The Priority Review, FDA actions, week of October 19, 2026: FDA approves first once-weekly insulin for type 2 diabetes in pediatric patients (priority review), 23 October 2026: https://thepriorityreview.com/news/fda-actions-week-of-2026-10-19
Reporting based on the sources above, accessed 24 October 2026. The Novo Nordisk announcement was read directly in full, and the Becker's report was read directly in full and cross-checked against it. MedClinicX did not conduct original reporting or interviews for this article. This article is news reporting, not medical advice. Families should discuss treatment options with their clinician. Corrections: contact us via https://medclinicx.com/contact